171 reports of this reaction
2.0% of all CARMUSTINE reports
#11 most reported adverse reaction
ACUTE MYELOID LEUKAEMIA is the #11 most commonly reported adverse reaction for CARMUSTINE, manufactured by Azurity Pharmaceuticals, Inc.. There are 171 FDA adverse event reports linking CARMUSTINE to ACUTE MYELOID LEUKAEMIA. This represents approximately 2.0% of all 8,401 adverse event reports for this drug.
Patients taking CARMUSTINE who experience acute myeloid leukaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE MYELOID LEUKAEMIA is a less commonly reported adverse event for CARMUSTINE, but still significant enough to appear in the safety profile.
In addition to acute myeloid leukaemia, the following adverse reactions have been reported for CARMUSTINE:
The following drugs have also been linked to acute myeloid leukaemia in FDA adverse event reports:
ACUTE MYELOID LEUKAEMIA has been reported as an adverse event in 171 FDA reports for CARMUSTINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE MYELOID LEUKAEMIA accounts for approximately 2.0% of all adverse event reports for CARMUSTINE, making it a notable side effect.
If you experience acute myeloid leukaemia while taking CARMUSTINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.